<DOC>
	<DOCNO>NCT01747720</DOCNO>
	<brief_summary>There evidence vitamin D could use reduce breast cancer risk . Randomized control trial would provide definitive evidence effect . However , trial breast cancer outcome expensive time-consuming . Use surrogate outcome advocate accelerate progress identification intervention could prevent breast cancer . Mammographic breast density one strong breast cancer risk indicator already use surrogate outcome several breast cancer prevention trial . The aim double-blind randomize control trial determine whether daily oral supplementation vitamin D3 ( 1,000 , 2,000 3,000 IU ) period 1 year reduces breast density premenopausal woman compare placebo . A total 376 woman ( 94 per arm ) live Quebec City recruit . Showing vitamin D reduces breast density would provide strong support idea vitamin D safe inexpensive approach prevention breast cancer .</brief_summary>
	<brief_title>Vitamin D Mammographic Breast Density</brief_title>
	<detailed_description>OBJECTIVES Primary : - determine whether add oral supplementation vitamin D3 ( cholecalciferol ) dose 1,000 , 2,000 3,000 IU/d baseline total vitamin D intake period 12 month reduces mammographic breast density among premenopausal woman moderate high risk breast cancer reside Quebec City area , Canada . Secondary : - ass net increase 25 ( OH ) D level result vitamin D3 supplementation ; - document compliance , safety , supplementation test dos vitamin D3 one year . OUTLINE This study double-blind , placebo-controlled , randomized trial among premenopausal woman live Quebec City area ≥ 20 % breast density baseline . The intervention consist addition , baseline total vitamin D intake food supplement , three different dos vitamin D3 ( 1000 , 2000 3000 IU/day ) period 12 month . There four arm trial : - Arm 1 : 1,000 IU vitamin D3/d ( 1 tablet vitamin D 1000 IU + 2 tablet placebo ) ; - Arm 2 : 2,000 IU vitamin D3/d ( 2 tablet vitamin D 1000 IU + 1 tablet placebo ) ; - Arm 3 : 3,000 IU vitamin D3/d ( 3 tablet vitamin D 1000 IU ) ; - Arm 4 : placebo ( 3 tablet placebo/d ) . Vitamin D tablet ( 1000 IU tablet ) placebo tablet undistinguishable size , shape , color taste , manufacture company .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>premenopausal baseline ; breast density least 20 % baseline ; normal baseline serum calcium ( 2,122,60 mmol/L ) serum creatinine ( 4585 μmol/L ) ; agree mammogram 12 month followup mammography clinic ( site ) one mammogram recruitment do . take &gt; 400 IU/day supplemental vitamin D refuse reduce ( ≤ 400 IU/day ) cease intake ; take &gt; 600 mg/day supplemental calcium refuse reduce ( ≤ 600 mg/day ) cease intake ; contraindication use vitamin D supplementation ( hypersensitivity vitamin D analogues ; history renal calculus hypercalcemia , hypervitaminosis D ) ; take medication suspect interact vitamin D : frequent use antacid contain magnesium aluminium ; regular use anticonvulsant ( phenytoin , phenobarbital ) , digoxin , cholestyramine , colestipol , orlistat , mineral oil ; personal history breast cancer ; personal history cancer nonmelanoma skin cancer within 5 last year ; breast reduction augmentation include breast implantation ( plan undergo surgery trial ) ; pregnant planning pregnancy next year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>mammographic breast density</keyword>
	<keyword>vitamin D</keyword>
	<keyword>prevention</keyword>
	<keyword>randomize control trial</keyword>
</DOC>